A Phase I, Open Label, Non-Randomized, Parallel Group, Pharmacokinetic Study in Subjects With Normal Renal Function, Moderate or Severe Renal Impairment Receiving a Single Dose of Oral 150 mg AZD3355.
Phase of Trial: Phase I
Latest Information Update: 21 Jan 2011
At a glance
- Drugs Lesogaberan (Primary)
- Indications Renal impairment
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 05 May 2010 Actual patient number (23) added as reported by ClinicalTrials.gov.
- 05 May 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
- 05 May 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.